You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

DEUTETRABENAZINE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for deutetrabenazine and what is the scope of patent protection?

Deutetrabenazine is the generic ingredient in two branded drugs marketed by Teva and Teva Branded Pharm, and is included in two NDAs. There are fifteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Deutetrabenazine has one hundred and forty-eight patent family members in thirty-four countries.

One supplier is listed for this compound.

Summary for DEUTETRABENAZINE
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for DEUTETRABENAZINE
Generic Entry Dates for DEUTETRABENAZINE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL
Generic Entry Dates for DEUTETRABENAZINE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, EXTENDED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for DEUTETRABENAZINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Vanderbilt University Medical CenterPhase 2/Phase 3
Fundacion Huntington Puerto RicoPhase 1
Teva Branded Pharmaceutical Products R&D, Inc.Phase 1/Phase 2

See all DEUTETRABENAZINE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for DEUTETRABENAZINE
Paragraph IV (Patent) Challenges for DEUTETRABENAZINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
AUSTEDO Tablets deutetrabenazine 6 mg, 9 mg and 12 mg 208082 2 2021-04-05

US Patents and Regulatory Information for DEUTETRABENAZINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-002 Apr 3, 2017 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE;ORAL 216354-001 Feb 17, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE;ORAL 216354-006 May 29, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-002 Apr 3, 2017 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE;ORAL 216354-003 Feb 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-002 Apr 3, 2017 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva AUSTEDO XR deutetrabenazine TABLET, EXTENDED RELEASE;ORAL 216354-007 May 29, 2024 RX No No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for DEUTETRABENAZINE

Country Patent Number Title Estimated Expiration
India 1662DEN2015 ⤷  Sign Up
China 114767672 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物 (Deuterated tetrabenazine or composition containing deuterated tetrabenazine) ⤷  Sign Up
Australia 2021288087 Osmotic dosage forms comprising deutetrabenazine and methods of use thereof ⤷  Sign Up
China 102186848 Benzoquinoline inhibitors of vesicular monoamine transporter 2 ⤷  Sign Up
Australia 2013318182 Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 ⤷  Sign Up
Poland 3265085 ⤷  Sign Up
Japan 2024058686 デューテトラベナジンを含む浸透性剤形及びその使用方法 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.